NEW YORK, NY / ACCESSWIRE / October 2, 2019 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit. If you suffered a loss, you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.
International Flavors & Fragrances Inc. (IFF)
Class Period: May 7, 2018 to August 5, 2019
Lead Plaintiff Deadline: October 11, 2019
Throughout the class period, International Flavors & Fragrances Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (1) Frutarom Industries Ltd. ("Frutarom"), which the Company acquired in 2018, had bribed customers in Russia and Ukraine; (2) senior management at Frutarom were aware of such improper payments; (3) as a result, Frutarom's financial results were materially overstated; (4) as a result of the improper payments, the Company was reasonably likely to face regulatory scrutiny; (5) the Company had not completed adequate due diligence before acquiring Frutarom; (6) as a result of the foregoing, the Company was unlikely to achieve purported synergies from the acquisition; and (7) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
Learn about your recoverable losses in IFF: http://www.kleinstocklaw.com/pslra-1/international-flavors-fragrances-inc-loss-submission-form?id=3767&from=1
CVS Health Corporation (CVS)
Class Period: on behalf of all former Aetna Inc. shareholders who acquired CVS Health Corporation (CVS) shares in exchange for their Aetna shares in connection with CVS's acquisition of Aetna on November 28, 2018.
Lead Plaintiff Deadline: October 15, 2019
According to the filed complaint, CVS made false and/or misleading statements in connection with its acquisition of Aetna and/or failed to disclose that: (a) by the end of 2017, CVS's financial condition and expected earnings had deteriorated as a result of rising costs and poor results being experienced in the long-term care ("LTC") unit associated with the 2015 acquisition of Omnicare; (b) in 2017, deteriorating conditions and prospects in CVS 's LTC unit prompted CVS to undertake hasty acquisitions of LTC pharmacies to compensate for the declining LTC business and/or mask the expected LTC goodwill impairment ahead of the planned Acquisition; (c) although negative LTC performance factors prompted CVS and the CVS Individual Defendants to make hasty LTC pharmacy acquisitions in 2017, those same negative factors were being overlooked and ignored for purposes of undertaking, disclosing, and reporting the results of LTC goodwill impairment tests throughout 2017, in violation of GAAP; (d) the LTC goodwill being carried on CVS's books as a result of the Omnicare acquisition was being carried at inflated values that would require billions of dollars in impairment charges that would be charged against earnings; and (e) as a result of the foregoing, CVS's true business metrics and financial prospects were not as the Offering Documents represented.
Learn about your recoverable losses in CVS: http://www.kleinstocklaw.com/pslra-1/cvs-health-corporation-loss-submission-form-2?id=3767&from=1
Farfetch Limited (FTCH)
Class Period: all persons and entities who purchased or otherwise acquired Farfetch Class A ordinary shares between September 21, 2018, and August 8, 2019, inclusive, including those who purchased or otherwise acquired Farfetch Class A ordinary shares pursuant and/or traceable to the registration statement and prospectus issued in connection with Company's September 21, 2018 initial public offering.
Lead Plaintiff Deadline: November 18, 2019
During the class period, Farfetch Limited allegedly made materially false and/or misleading statements and/or failed to disclose that: (1) the Company would refuse to reduce merchandise prices to match the rest of the market; (2) this sub-optimal pricing strategy rendered the Company's platform highly susceptible to underpricing by competitors, despite what Defendants touted as a "superior" platform; and (3) as a result, the Company's past and projected Platform Gross Merchandise Value growth rates were foreseeably unsustainable. As a result of the foregoing, Defendants' statements about the Company's business strategy and growth prospects lacked a reasonable basis at all relevant times.
Learn about your recoverable losses in FTCH: http://www.kleinstocklaw.com/pslra-1/farfetch-loss-submission-form?id=3767&from=1
Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.
J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.
SOURCE: The Klein Law Firm
View source version on accesswire.com: